Portal de Periódicos da CAPES

Evidence to Support a Continued Stage Migration and Decrease in Prostate Cancer Specific Mortality

2006; Lippincott Williams & Wilkins; Volume: 175; Issue: 3 Linguagem: Inglês

10.1016/s0022-5347(05)00419-2

1527-3792

Shira Galper, Ming‐Hui Chen, William J. Catàlona, Kimberly A. Roehl, Jerome P. Richie, Anthony V. D’Amico,

Global Cancer Incidence and Screening

No AccessJournal of UrologyAdult urology1 Mar 2006Evidence to Support a Continued Stage Migration and Decrease in Prostate Cancer Specific Mortality Shira L. Galper, Ming-Hui Chen, William J. Catalona, Kimberly A. Roehl, Jerome P. Richie, and Anthony V. D'Amico Shira L. GalperShira L. Galper Tufts University School of Medicine, Boston, Massachusetts , Ming-Hui ChenMing-Hui Chen Department of Statistics, University of Connecticut, Storrs, Connecticut , William J. CatalonaWilliam J. Catalona Department of Urology, Northwestern Feinberg School of Medicine, Chicago, Illinois , Kimberly A. RoehlKimberly A. Roehl Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri , Jerome P. RichieJerome P. Richie Department of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, Massachusetts , and Anthony V. D'AmicoAnthony V. D'Amico Department of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, Massachusetts View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)00419-2AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We evaluated whether the proportion of patients with a postoperative PSA-DT less than 3 months, a surrogate for PCSM, decreased significantly during the PSA era. Materials and Methods: Between July 1988 and July 2002, 3,719 men with clinically localized prostate cancer treated with RP comprised the study cohort. A chi-square metric was used to compare the preoperative and postoperative characteristics, 5-year actual PSA failure rates, and PSA-DTs for patients treated during the 2 equally divided eras of the early PSA era, July 1988 to July 1995 and the late PSA era, August 1995 to July 2002. Results: Patients presenting in the more recent PSA era were of younger age (p <0.0001), with earlier stage (p <0.0001) and lower grade disease (p = 0.01). Similarly, patients had lower grade (p <0.001), stage (p <0.0001), and positive margin (p <0.0001) and lymph node rates (p = 0.0002) at RP. The 5-year actual PSA failure rates decreased from 14.3% in the early PSA era to 2.5% in the later PSA era (p <0.0001). There was a 37% reduction in the proportion of patients with a PSA-DT less than 3 months, corresponding to a decrease in absolute magnitude from 9% to 5.7% between the 2 eras. Absolute reductions of 3.1% and 9% were also noted for the proportion of PSA-DTs of 3 to 5.99 months and 6 to 11.99 months, respectively, whereas PSA-DTs of 12 months or greater increased by 15.3%. Conclusions: During the recent PSA era, postoperative PSA failure has significantly decreased and PSA-DTs have increased, suggesting that PCSM will continue to decrease. References 1 : Cancer statistics, 2004. CA Cancer J Clin2004; 54: 8. Google Scholar 2 : Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA1993; 270: 948. Google Scholar 3 : National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening. Urology1998; 52: 444. Google Scholar 4 : Influence of prostate-specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice. Mayo Clin Proc1998; 73: 401. Google Scholar 5 : Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA1997; 277: 1445. Google Scholar 6 : Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol2001; 166: 416. Link, Google Scholar 7 : Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. Urology2002; 60: 458. Google Scholar 8 : Natural history of progression after PSA elevation following radical prostatectomy. JAMA1999; 281: 1591. Google Scholar 9 : PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc2001; 76: 576. Google Scholar 10 : Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys2000; 48:: 629. Google Scholar 11 : Determinants of prostate cancer specific survival following radiation therapy during the prostate specific antigen era. J Urol, part 22003; 170:: S42. Link, Google Scholar 12 : Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst2003; 95: 1376. Google Scholar 13 : The prostate, lung, colon, and ovarian (PLCO) cancer screening trial status and promise. Urol Oncol2004; 22: 358. Google Scholar 14 : Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary Cancer trial. Int J Cancer2002; 97:: 237. Google Scholar 15 : Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer 5 year results. J Urol2002; 167: 112. Link, Google Scholar 16 : AJCC Cancer-Staging Manual. New York: Springer-Verlag2002: 337. Google Scholar 17 : Survival Analysis. New York: Springer1997: 96. pp. and 229–268. Google Scholar 18 : Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol2003; 21: 2163. Google Scholar 19 : Are increasing 5-year survival rates evidence of success against cancer?. JAMA2000; 283: 2975. Google Scholar 20 : Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med2005; 352: 1977. Google Scholar © 2006 by American Urological AssociationFiguresReferencesRelatedDetailsCited ByAtala A (2018) Re: Vitamin D3 Prevents Calcium-Induced Progression of Early-Stage Prostate Tumors by Counteracting TRPC6 and Calcium Sensing Receptor UpregulationJournal of Urology, VOL. 199, NO. 5, (1115-1116), Online publication date: 1-May-2018.Eifler J, Levinson A, Hyndman M, Trock B and Pavlovich C (2018) Pelvic Lymph Node Dissection is Associated With Symptomatic Venous Thromboembolism Risk During Laparoscopic Radical ProstatectomyJournal of Urology, VOL. 185, NO. 5, (1661-1666), Online publication date: 1-May-2011.Salonia A, Gallina A, Matloob R, Rocchini L, Saccà A, Abdollah F, Colombo R, Suardi N, Briganti A, Guazzoni G, Rigatti P and Montorsi F (2018) Is Sperm Banking of Interest to Patients With Nongerm Cell Urological Cancer Before Potentially Fertility Damaging Treatments?Journal of Urology, VOL. 182, NO. 3, (1101-1107), Online publication date: 1-Sep-2009. Volume 175Issue 3March 2006Page: 907-912 Advertisement Copyright & Permissions© 2006 by American Urological AssociationKeywordsprostate-specific antigenprostatectomymass screeningtreatment failureprostatic neoplasmsMetricsAuthor Information Shira L. Galper Tufts University School of Medicine, Boston, Massachusetts Nothing to disclose. More articles by this author Ming-Hui Chen Department of Statistics, University of Connecticut, Storrs, Connecticut Nothing to disclose. More articles by this author William J. Catalona Department of Urology, Northwestern Feinberg School of Medicine, Chicago, Illinois Financial interest and/or other relationship with Beckman Coulter. More articles by this author Kimberly A. Roehl Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri Nothing to disclose. More articles by this author Jerome P. Richie Department of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, Massachusetts Nothing to disclose. More articles by this author Anthony V. D'Amico Department of Radiation Oncology, Brigham and Women's Hospital and Dana Farber Cancer Institute, Boston, Massachusetts Nothing to disclose. More articles by this author Expand All Advertisement PDF DownloadLoading ...